Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Lamarca, Angela Palmer, D. Wasan, H. S. Ross, P. Ma, Y. T. Arora, A. Falk, S. Gillmore, R. Wadsley, J. Patel, K.
Lamarca, Angela
Palmer, D.
Wasan, H. S.
Ross, P.
Ma, Y. T.
Arora, A.
Falk, S.
Gillmore, R.
Wadsley, J.
Patel, K.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Lamarca A, Palmer D, Wasan HS, Ross P, Ma YT, Arora A, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology. 2022 Sep;33(7):S564-S5. PubMed PMID: WOS:000866211600054.